



Nanotechnology in Ocular Drug Delivery

Guest Editors:

Dr. Priyanka Agarwal

Buchanan Ocular Therapeutics
Unit, Department of
Ophthalmology, University of
Auckland, Auckland 1142, New
Zealand

**Prof. Dr. Thakur Raghu Raj
Singh**

Chair in Pharmaceutics, McClay
Research Centre, School of
Pharmacy, Queen's University
Belfast, Medical Biology Centre,
97 Lisburn Road, Belfast BT9 7BL,
UK

Deadline for manuscript
submissions:
closed (31 August 2022)

Message from the Guest Editors

Dear Colleagues,

The eye is a complex and dynamic organ that presents unique challenges for drug delivery. With formidable tissue barriers and a rich perfusion of blood vessels, the eye significantly restricts the entry of foreign substances; meanwhile, due to its vulnerable nature, the toxicity and irritation potential of conventionally used formulations and excipients are often heightened.

In recent years, “nanomedicine” has been extensively investigated due to its proposed advantages of sustained and targeted drug delivery, reduced adverse effects, and enhanced bioavailability of hydrophobic and hydrophilic drugs, macromolecules, proteins, and peptides as well as biological vectors, including genes and antibodies. Thus, nanotechnology may facilitate the delivery of ocular therapeutics in clinically relevant concentrations to the anterior, and possibly even posterior, ocular tissues.

This Special Issue highlights new research in nanomedicine for both the topical and intraocular administration of ocular therapeutics and its application in the treatment and management of ocular pathologies.

Prof. Dr. Thakur Raghu Raj Singh
Dr. Priyanka Agarwal
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma